Trimetazidine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Trimetazidine
- Trimetazidine: From Angina Pectoris to Mitochondrial Oxidative Phosphorylation Disorder due to Nuclear DNA Anomalies
Trimetazidine: From Angina Pectoris to Mitochondrial Oxidative Phosphorylation Disorder due to Nuclear DNA Anomalies
One-Sentence Summary
Trimetazidine is a metabolic modulator historically used as an anti-anginal agent for stable angina pectoris. The TxGNN model predicts it may be effective for mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies, but this prediction is currently supported by no clinical trials and no publications — it rests purely on mechanistic reasoning.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this Evidence Pack (no UK licence text available); internationally, trimetazidine has historically been used as a metabolic anti-anginal agent for stable angina pectoris |
| Predicted New Indication | Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies |
| TxGNN Prediction Score | 98.83% |
| Evidence Level | L5 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known pharmacological information, trimetazidine is a fatty acid oxidation (pFOX) inhibitor that shifts cellular energy metabolism away from fatty acid β-oxidation towards glucose oxidation, a more oxygen-efficient pathway. Its efficacy in angina pectoris — where myocardial oxygen supply is limited — is well documented internationally.
The rationale linking this mechanism to mitochondrial oxidative phosphorylation (OXPHOS) disorders is that, by promoting glucose oxidation, trimetazidine could theoretically offer an alternative energy-generating route for cells with defective OXPHOS capacity caused by nuclear DNA anomalies. However, this is explicitly flagged in the Evidence Pack as a purely mechanistic inference, without any supporting clinical or preclinical data. Diseases in this category are also highly heterogeneous in aetiology, meaning a single metabolic mechanism is unlikely to apply uniformly across the group. This prediction should therefore be treated with considerable caution.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Trimetazidine currently holds no marketing authorisation in the United Kingdom (total licences: 0); its market status is recorded as Not Marketed. No licence-level product, dosage form, or approved-indication data are available in this Evidence Pack.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: Key warnings, contraindications and drug–drug interaction data for trimetazidine are currently unavailable in this Evidence Pack — obtaining the SmPC/label warnings is flagged as a Blocking data gap, DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (mitochondrial OXPHOS disorder due to nuclear DNA anomalies) has no clinical trial or literature evidence — it is evidence level L5, a computational prediction only. Combined with the high aetiological heterogeneity of this disease group and the lack of any confirmed mechanism of action, there is insufficient basis to advance this specific indication.
To proceed, the following is needed:
- Confirmed mechanism of action data via DrugBank (DG002)
- UK SmPC-level warnings and contraindications, required before any safety pre-screening can begin (DG001, Blocking)
- Preclinical or mechanistic studies specifically testing trimetazidine in nuclear-DNA-related OXPHOS disorders
- Separate evaluation of the endolymphatic hydrops / Ménière’s disease signal (rank 2 in this Evidence Pack), which — unlike the top-ranked prediction — is supported by six identified publications, including historical double-blind comparative trials of trimetazidine versus betahistine in vertigo/Ménière’s disease; this may represent a more evidence-ready repurposing candidate than the current top prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.